— Know what they know.
Not Investment Advice

IBRX Dividends

ImmunityBio, Inc.
1W: -7.2% 1M: -7.5% 3M: +12.1% YTD: +286.6% 1Y: +226.8% 3Y: +524.8% 5Y: -12.5%
$8.63
+0.82 (+10.50%)
After Hours: $8.60 (-0.03, -0.35%)
Weekly Expected Move ±11.1%
$6 $7 $8 $9 $10
NASDAQ · Healthcare · Biotechnology · Tech Score Sell · Power 37 · $9.1B mcap · 115M float · 10.13% daily turnover · Short 61% of daily vol
Credit Risk of going bust: higher than 78% of companies Debt: 8.9% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the third-riskiest tenth, about 1 in 140 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.14 (down 98%), ImmunityBio, Inc. would be worth roughly what it owes.
Total debt $813.1M against a stock market value of $8.28B.
Distance to default 2.77 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $387.2M (short-term plus half of long-term), stock volatility 101.1%; Altman Z'' -30.40. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
IBRX does not currently pay a dividend.
This company has no dividend payment history on record.

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms